While the company’s formulation sales in India, Emerging markets and Rest of the world reported an expansion, the US formulation sales reported a YoY decline of 2.5 per cent to $464 million (around ₹3,940 crore) Read more: https://pharma.economictimes.indiatimes.com/news/financial-performance/sun-pharma-reports-q4-revenue-growth-despite-declining-us-sales/121350257